Results 131 to 140 of about 28,675 (247)

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Annals of Clinical and Translational Neurology, Volume 13, Issue 8, Page 1697-1701, August 2026.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos, Marwa Al‐Dubai, Denise Walther, Dominic Borie, Jan D. Lünemann, Marc Pawlitzki, Sven G. Meuth, Solveig Henneicke, Stefan Vielhaber, Stefanie Schreiber   +9 more
wiley   +1 more source

Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis. [PDF]

Front Immunol
Buhelt S, Hansen MB, Søndergaard HB, El Mahdaoui S, Hansen MM, Mahler MR, Romme Christensen J, Sellebjerg F.   +7 more
europepmc   +1 more source

Histopathological Evidence of Neurodegenerative Pathology in Epilepsy: A Systematic Review

Annals of Clinical and Translational Neurology, Volume 13, Issue 8, Page 1530-1542, August 2026.
ABSTRACT Epilepsy affects > 50 million people worldwide and is associated with a disproportionate burden of cognitive impairment. Emerging evidence suggests that neurodegenerative proteinopathies, particularly hyperphosphorylated tau (p‐tau) and amyloid‐β (Aβ), may contribute to cognitive dysfunction in people with epilepsy (PWE), even in the absence ...
Syeda Amrah Hashmi, Aleksander Luniewski, Vanessa Smith, Matthew McCord, Jaideep Kapur, Mark Quigg, Catherine Joshua, Ifrah Zawar   +7 more
wiley   +1 more source

Identification of diagnostic biomarkers for relapsing-remitting multiple sclerosis in plasma by mass spectrometry-based proteomics. [PDF]

J Neuropathol Exp Neurol
García-Silva VM, Chicano-Galvez E, García-Sánchez MI, Peralbo-Molina Á, Hernández-Valladares M.   +4 more
europepmc   +1 more source

Early Upper Limb Motor Impairment in Multiple Sclerosis Across EDSS Levels: A Case–Control Study

Brain and Behavior, Volume 16, Issue 8, August 2026.
Upper limb function is impaired in people with multiple sclerosis compared with healthy controls, even at low levels of neurological disability. Patients are stratified by Expanded Disability Status Scale (EDSS) score (≤3.5 and >3.5) and assessed using objective upper limb measures.
Aitor Blázquez‐Fernández, Selena Marcos‐Antón, Cecilia Estrada‐Barranco, Patricia Martín‐Casas, Rosa María Ortiz‐Gutiérrez, Carmen Jiménez‐Antona, Sofía Laguarta‐Val, Roberto Cano‐de‐la‐Cuerda   +7 more
wiley   +1 more source

Effectiveness and Safety of Rituximab in Filipino Patients With Relapsing-Remitting Multiple Sclerosis: A Real-World Retrospective Cohort Study in a Resource-Limited Setting. [PDF]

Cureus
Co APC, De la Paz FGE, Aninang MT, Del Mundo MES, Nobleza CMN, Damian LF.   +5 more
europepmc   +1 more source

Retinal Layer Thickness for Risk Stratification of Progression Independent of Relapse Activity in Relapsing‐Remitting Multiple Sclerosis

Brain and Behavior, Volume 16, Issue 8, August 2026.
This study assessed the prognostic value of optical coherence tomography‐derived thicknesses of the peripapillary retinal nerve fiber and ganglion cell‐inner plexiform layer for identifying people with relapsing‐remitting multiple sclerosis at risk of progression independent of relapse activity (PIRA) from two German centers.
Andre Braginets, Frederike Cosima Oertel, Eva‐Maria Strauß, Carla Leutloff, Tanja Schmitz‐Hübsch, Friedemann Paul, Susanna Asseyer, Rebecca Wicklein, Bernhard Hemmer, Klemens Ruprecht, Hanna Gwendolyn Zimmermann, Benjamin Knier, Ting‐Yi Lin   +12 more
wiley   +1 more source

The prevalence of comorbid migraine in multiple sclerosis: do multiple sclerosis and migraine really coexist? [PDF]

J Oral Facial Pain Headache
Kępczyńska K, Sochań P, Bednarczyk N, Sochań PJ, Domitrz W, Kochanowski J, Domitrz I.   +6 more
europepmc   +1 more source

Oligodendrocyte and Astrocyte Dynamics During Short‐Term Cuprizone Treatment

Brain and Behavior, Volume 16, Issue 8, August 2026.
Early cuprizone exposure (3 days to 1 week) results in the loss of mature oligodendrocytes and a shift in astrocyte subtypes before overt demyelination occurs. A1 astrocytes remained non‐significant; however, A2 astrocytes increased, indicating a protective, pro‐repair astrocyte–oligodendrocyte interaction that may be crucial for therapeutic ...
Lana Frankle, Mercy Oso, Amanda Riley, Riely Tomor, Davi Cecconi Checan, Hannah Lee, Kole Jarzembak, Sarah Sternbach, John Shelestak, Jennifer McDonough, Robert Clements   +10 more
wiley   +1 more source

Preliminary Psychometric Evaluation of the Romanian Version of the Hospital Anxiety and Depression Scale in Relapsing-Remitting Multiple Sclerosis. [PDF]

J Clin Med
Böckels L, Lisnic V, Alexa D, Belenciuc A, Crețu RA, Ropot D, Bîlcu RV, Cuciureanu DI.   +7 more
europepmc   +1 more source